Phase 2 studies of brolucizumab show similar efficacy to aflibercept (Eylea) for wet age-related macular degeneration (AMD) and the drug is now advancing to Phase 3 trials. Wet AMD is becoming more prevalent and the higher the number of treatment options, the better. What is interesting is that the brolucizumab group in the study may have experienced higher efficacy according to these early results. We will await the results of the Phase 3 trials in 2018.

https://www.aao.org/headline/new-anti-vegf-agent-advances-to-phase-3-trials